PolyPeptide Group AG (LON:0AAJ)

Market Cap	827.55M +5.2%
Revenue (ttm)	316.17M +14.0%
Net Income	-29.76M
EPS	-0.89
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	603
Average Volume	27,676
Open	26.30
Previous Close	26.25
Day's Range	25.70 - 26.30
52-Week Range	13.82 - 32.65
Beta	1.12
RSI	43.46
Earnings Date	Mar 12, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1952
• Employees: 1,400
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0AAJ

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR